Back to top
more

Bristol Myers Squibb (BMY)

(Delayed Data from NYSE)

$43.36 USD

43.36
10,369,433

-0.67 (-1.52%)

Updated May 20, 2024 04:00 PM ET

After-Market: $43.41 +0.05 (0.12%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (86 out of 249)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

New York-based Bristol-Myers Squibb is a one of the leading global specialty bio-pharmaceutical companies focused on the development of treatments targeting serious diseases. Backed by its blockbuster immune-oncology drug, Opdivo, Bristol-Myers has a strong oncology portfolio, consisting of other drugs like Revlimid, Sprycel, Yervoy and Empliciti. Beyond oncology, the company has important immunology and cardiovascular drugs like Orencia and Eliquis, which diversify its portfolio. Notably, in the cardiovascular space, Eliquis is now the global leading oral anti-coagulant drug. The company continues to experience growth in both the Eliquis brand and the market, while also advancing its Factor XIa inhibitor program..

Bristol-Myers (BMY) Q4 Earnings Miss Estimates

Bristol-Myers (BMY) reported fourth quarter earnings of 63 cents on revenues of $5.23 billion.

    Drug Stock Earnings to Watch on Jan 26: BIIB, CELG & BMY

    How will these three drug stocks, CELG, BMY and BIIB, which are all scheduled to report Q4 results on Jan 26, fare this earnings season?

      Gilead (GILD) HCV Therapy Application Validated in Europe

      Gilead Sciences, Inc. (GILD) announced that its MAA for once-daily, single tablet regimen of Sovaldi, velpatasvir 100 mg and voxilaprevir 100 mg (SOF/VEL/VOX) for HCV treatment has been fully validated.

        Bristol-Myers Settles Litigation with Merck for Keytruda

        Bristol-Myers Squibb Company (BMY) along with partner Ono Pharmaceutical Company, Ltd. announced that both the companies have signed a global patent license agreement with Merck & Co., Inc. (MRK) to settle all litigation related to Keytruda.

          Sweta Killa headshot

          Can Q4 Earnings Revitalize Healthcare ETFs?

          The Q4 earnings could bring some near-term relief given that the sector is expected to post earnings growth of 2.9% and revenue growth of 5.6%.

            Bristol-Myers to Not Seek Accelerated Approval for Opdivo+Yervoy

            Bristol-Myers (BMY) won't seek an accelerated approval in the U.S. for the combination of its two immuno-oncology treatments Opdivo plus Yervoy for the first-line lung cancer.

              Bristol-Myers (BMY) Q4 Earnings: Will the Stock Disappoint?

              Bristol-Myers (BMY) is set to report fourth-quarter 2016 results on Jan 26. It reported a positive earnings surprise of 18.46% in the last quarter.

                AstraZeneca Offers Update on Immuno-Oncology Program

                AstraZeneca (AZN) provided an update on its late-stage immuno-oncology program for first-line NSCLC.

                  ARIAD: Acquisition by Takeda Bodes Well, Competition a Risk

                  On Jan 13, we issued an updated report on ARIAD Pharmaceuticals, Inc. (ARIA).

                    Arpita Dutt headshot

                    Pharma Stock Roundup: Trump Targets Pharma Again, Merck Up on Keytruda News

                    The sector was once again slammed by president-elect Donald Trump's comments this week regarding drug pricing.

                      Sweta Killa headshot

                      Trump Attacks Biotech & Pharma: ETFs Bleed

                      Trump pledged to initiate a bidding process for drug cost that shed roughly $24.6 billion in 20 minutes from the nine biggest pharmaceutical companies by market cap.

                        Roche Gets Priority Review for Immunotherapy Drug Tecentriq

                        Roche Holding AG's (RHHBY) Genentech announced that the FDA has accepted the company's supplemental Biologics License Application (sBLA) and granted Priority Review for cancer immunotherapy, Tecentriq.

                          Bristol-Myers, GeneCentric Tie Up for Opdivo Biomarker Study

                          Bristol-Myers (BMY) and GeneCentric Diagnostics inked an exploratory biomarker research collaboration.

                            Bristol-Myers, J&J Ink Immunotherapy Research Collaboration

                            Bristol-Myers (BMY) entered into an immunotherapy clinical research collaboration with Johnson & Johnson to evaluate a combination of Opdivo and Darzalex.

                              Arpita Dutt headshot

                              Pharma Stock Roundup: PCSK9 Inhibitor Praluent in News, Allergan's Preliminary 2017 View

                              Key highlights this week include a court injunction blocking sales of PCSK9 inhibitor Praluent and preliminary guidance from Allergan (AGN).

                                Bristol-Myers Extends Deal with Five Prime Therapeutics

                                Bristol-Myers (BMY) has exercised its option to extend the research term of the existing collaboration agreement with Five Prime Therapeutics (FPRX).

                                  4 Reasons Why Pfizer (PFE) Could be a Great Pick in 2017

                                  Pfizer's shares surpassed that of large-cap pharma industry in 2016. The stock rose 0.6% in 2016.

                                    ARIAD Stock Beats Industry in 2016, Iclusig Sales Strong

                                    Shares of ARIAD Pharma surged 98.4% year to date and outperformed the Zacks classified Medical-Drugs industry that declined 25.4%.

                                      AbbVie's Humira and Imbruvica Drive Performance in 2016

                                      AbbVie Inc.'s (ABBV) share price is up 5.9% so far this year.

                                        Arpita Dutt headshot

                                        Pharma Stock Roundup: Cempra Plunges to 52-Week Low, Shire Drug Label Expanded

                                        Key highlights this week include complete response letters from the FDA for a couple of companies with Cempra (CEMP) plunging to a 52-week low.

                                          Portola Betrixaban Accepted for Review in U.S. & EU, Stock Up

                                          Shares of Portola (PTLA) surged 33.8% after the FDA granted priority review to anticoagulant, betrixaban. Betrixaban was also accepted by the EMA for review.

                                            Arpita Dutt headshot

                                            Pharma Stock Roundup: J&J Back in Talks with Actelion, Teva Settles Corruption Probe

                                            J&J (JNJ) and Actelion are back in the limelight with the companies in exclusive talks regarding a possible deal.

                                              Bristol-Myers, Calithera Team Up for Opdivo/CB-839 Combo

                                              Bristol-Myers Squibb Company (BMY) announced a clinical trial collaboration with Calithera Biosciences, Inc. (CALA).

                                                Bristol-Myers, PsiOxus Ink Deal for Oncolytic Virus Therapy

                                                Bristol-Myers (BMY) inks a deal with PsiOxus for an early-stage oncolytic virus candidate, NG-348.

                                                  The Zacks Analyst Blog Highlights: Bristol-Myers, Shell, Facebook, Baker Hughes, Eli Lilly and Fifth Third Bancorp

                                                  The Zacks Analyst Blog Highlights: Bristol-Myers, Shell, Facebook, Baker Hughes, Eli Lilly and Fifth Third Bancorp